Micafungina Accord

Micafungin, the active ingredient in Micafungina Accord, is an echinocandin presented as an injectable solution for intravenous use. It is indicated for the treatment of invasive candidiasis, esophageal candidiasis, and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation, with off‑label use reported for invasive aspergillosis.

GNH USA supplies Micafungina Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product complies with European Union regulatory standards and is distributed to healthcare facilities across multiple continents.

Micafungin is an echinocandin antifungal used to treat invasive fungal infections.

- Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves mucosal Candida infection causing pain and dysphagia. - Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infection during periods of severe immunosuppression. - Invasive aspergillosis (off‑label): may be employed in selected cases where alternative therapies are unsuitable.

Micafungin may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Fever: transient rise in body temperature, usually mild and self‑limiting. - Nausea: mild to moderate sensation of stomach upset, may occur during or after infusion. - Elevated liver enzymes: temporary increase in ALT/AST levels, typically reversible after discontinuation.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury presenting with jaundice, elevated bilirubin, and hepatic dysfunction. - Anaphylaxis: acute, potentially life‑threatening hypersensitivity reaction with rash, bronchospasm, and hypotension. - Severe hypotension: sudden drop in blood pressure during infusion, requiring medical intervention.

When using Micafungin, several precautions should be observed to minimize risk and ensure optimal therapy. - Renal function: assess baseline kidney function and monitor during treatment in patients with pre‑existing renal impairment. - Hepatic function: evaluate liver enzymes before initiation and periodically thereafter, adjusting therapy if significant abnormalities develop. - Drug interactions: review concomitant medications, especially those affecting CYP3A4, to avoid altered micafungin exposure. - Pregnancy and lactation: prescribe only if the potential benefit justifies the potential risk to the fetus or infant. - Infusion monitoring: administer under medical supervision, observe for infusion‑related reactions, and be prepared to manage hypersensitivity. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the solution.

Micafungin can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce micafungin plasma concentrations, compromising efficacy. - Co‑administration with other echinocandins: increased risk of additive toxicity without clinical benefit.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole, voriconazole): may increase micafungin levels, requiring dose adjustment or close monitoring. - Immunosuppressants (e.g., cyclosporine, tacrolimus): potential for increased exposure; monitor drug levels and adjust as needed. - Anticoagulants (e.g., warfarin): possible alteration of INR; check coagulation parameters regularly.